Literature DB >> 8682120

Prevalence of left ventricular hypertrophy in a hypertensive population.

J Tingleff1, M Munch, T J Jakobsen, C Torp-Pedersen, M E Olsen, K H Jensen, T Jørgensen, M Kirchoff.   

Abstract

AIMS: This investigation was set up to study the prevalence of left ventricular hypertrophy in a hypertensive population with reference to a normotensive control group. From the general population 3498 men and women aged 35, 45, 55 and 65 years old were invited to a health examination. Participants with blood pressure above 160 mmHg systolic or 95 mmHg diastolic or those taking antihypertensive medication or having done so during the previous 6 months were asked to undergo an echocardiographic examination. Normotensive controls were randomly selected from the same population. Of 552 participants in the final study population, 194 were normotensive controls and 358 were in the hypertensive group. Echocardiographic measurements were made according to the Penn conventions and indexed for body surface. Cut-off values for left ventricular hypertrophy were 134 g.m-2 for males and 102 g.m-2 for women.
RESULTS: Overall, the prevalence of left ventricular hypertrophy was 14%/20% (men/women) in normotensives and 25%/26% in hypertensives (P < 0.01). After subdivision by age and sex, there was a significant difference in the prevalence of left ventricular hypertrophy between normotensives and hypertensives only in the 65-year-old group (P < 0.02 for males and P < 0.05 for females).
CONCLUSIONS: The association between blood pressure and left ventricular hypertrophy in the general population is weak. Left ventricular hypertrophy is only significantly more frequent among hypertensives as compared to normotensives in older people.

Entities:  

Mesh:

Year:  1996        PMID: 8682120     DOI: 10.1093/oxfordjournals.eurheartj.a014672

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

Review 1.  Epidemiology of risk factors for hypertension: implications for prevention and therapy.

Authors:  M Kornitzer; M Dramaix; G De Backer
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

2.  Complete reversal of hypertensive cardiomyopathy after initiating combined antihypertensive therapy.

Authors:  Marijn J Holl; Sweder W van de Poll; Michelle Michels
Journal:  BMJ Case Rep       Date:  2016-04-08

3.  The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

Authors:  Alain J Nordmann; Murray Krahn; Alexander G Logan; Gary Naglie; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Short-term repeatability of electrocardiographic criteria of left ventricular hypertrophy.

Authors:  Michelle L Meyer; Elsayed Z Soliman; Dominique Drager; Gerardo Heiss
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-09-09       Impact factor: 1.468

5.  A randomized general population study of the effects of repeated health checks on incident diabetes.

Authors:  Tea Skaaby; Torben Jørgensen; Allan Linneberg
Journal:  Endocrine       Date:  2018-02-07       Impact factor: 3.633

6.  Correlates of left ventricular mass in hypertensive Nigerians: an echocardiographic study.

Authors:  O S Ogah; A E Bamgboye
Journal:  Cardiovasc J Afr       Date:  2010 Mar-Apr       Impact factor: 1.167

7.  Implantable Cardioverter-defibrillator Therapy for Syncope: An Educational Example of a Multicomponent Electrocardiographic Differential Diagnosis and the Application of Clinical Trial Data to an Individual Patient.

Authors:  Daniel N Pugliese; James A Reiffel
Journal:  J Innov Card Rhythm Manag       Date:  2019-10-15

8.  Cardiac mechanical efficiency is preserved in primary cardiac hypertrophy despite impaired mechanical function.

Authors:  June-Chiew Han; Kenneth Tran; David J Crossman; Claire L Curl; Parisa Koutsifeli; Joshua P H Neale; Xun Li; Stephen B Harrap; Andrew J Taberner; Lea M D Delbridge; Denis S Loiselle; Kimberley M Mellor
Journal:  J Gen Physiol       Date:  2021-06-28       Impact factor: 4.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.